Authors:
Peter C Richmond, Helen S Marshall, Michael D Nissen, Qin Jiang, Kathrin U Jansen,Maria Garcés-Sánchez, Federico Martinón-Torres, Johannes Beeslaar, Leszek Szenborn, Jacek Wysocki, Joseph Eiden, Shannon L Harris,Thomas R Jones, John L Perez,on behalf of the 2001 Study Investigators
Authors notes:
The Lancet Infectious Diseases, Available online 6 May 2012, ISSN 1473-3099, 10.1016/S1473-3099(12)70087-7.
Keywords:
Safety, immunogenicity, tolerability, meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine, healthy adolescents, a randomised, single-blind, placebo-controlled, phase 2 trial
Abstract
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent recombinant factor H-binding protein vaccine (recombinant lipoprotein 2086) has been developed to provide broad coverage against diverse invasive meningococcus serogroup B strains. Our aim was to test the immune response of this vaccine.
Media release: New vaccine shows promise in protecting against common cause of meningitis (May, 2012)